UCL Business

MeiraGTx Reports First Quarter 2024 Financial and Operational Results

Retrieved on: 
четверг, мая 9, 2024
FDA, Research, UCL Business, Weight loss, IND, Oxyntomodulin, Visual acuity, RIX, Oral medicine, American Academy, Brain, STN, Facial muscles, Technology transfer, Janssen Pharmaceuticals, Appetite, BLA, MHRA, Messenger, Subthalamic nucleus, Safety, Diabetes, Insurance, RNA, AAOM, AAV, Dopamine, Obesity, DNA, Autoimmune disease, Motor cortex, Treatment, Pros, GMP, GIP, Clinical trial, File, PSMA, Sale, Radiation, Neurodegenerative disease, DSM-IV codes, Saliva, Health care, Xerostomia, Patient, Riboswitch, Gene, Peptide, Head, PYY, Pharmaceutical industry

LONDON and NEW YORK, May 09, 2024 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced financial and operational results for the first quarter ended March 31, 2024, and provided a corporate update.

Key Points: 
  • MeiraGTx anticipates receiving an additional $15 million in near-term milestone payments later in 2024.
  • As of March 31, 2024, MeiraGTx had cash and cash equivalents of approximately $119.2 million and in April 2024, the Company collected $19.7 million in receivables which were due in the first quarter of 2024, effectively increasing the cash balance to $138.9 million.
  • The increase of $0.6 million was due to higher interest rates and cash balances during 2024.
  • Interest expense was $3.3 million for the three months ended March 31, 2024, compared to $3.1 million for the three months ended March 31, 2023.

Lenire Biosciences Completes License Agreement with University College London for VSN16R, A Novel Clinical Candidate Treatment for Fragile X Syndrome

Retrieved on: 
четверг, июня 16, 2022
Multiple sclerosis, Myalgia, Spasticity, Patent, Therapy, Attention deficit hyperactivity disorder predominantly inattentive, Attention, Learning, 2009 Davis Cup, University College London, Anxiety, Residential treatment center, Technology, Cincinnati, Attention deficit, Company, Cincinnati Children's Hospital Medical Center, Human, Research, BK, Professor, Autism, UCL Business, Psychiatry, Intellectual disability, Patient, Biomedical Research, UCL, Attention deficit hyperactivity disorder, Disorder, SAN, FXS, Fragile X syndrome, GLOBE, Prevalence, Syndrome, Pharmaceutical industry

The development of this technology was supported by UCL Business (UCLB), the commercialization company of UCL.

Key Points: 
  • The development of this technology was supported by UCL Business (UCLB), the commercialization company of UCL.
  • FXS is a rare, inherited condition that can cause issues including developmental delays, learning and behavioural difficulties, physical abnormalities, anxiety, attention or hyperactivity disorders and autism spectrum disorder.
  • FXS is the most prevalent inherited form of intellectual disability and a leading cause of autism spectrum disorder.
  • Lenire Biosciences is privately held, clinical stage biopharmaceutical company that is developing novel, patent protected therapeutics for the treatment of Fragile X Syndrome (FXS), a leading cause of intellectual disability world-wide that also presents with anxiety, attention deficit, hyperactivity, autism spectrum behaviors and other disabling symptoms.

Alchip Technologies Offers 3nm ASIC Design Services

Retrieved on: 
среда, июня 15, 2022
Technology, Application-specific integrated circuit, Info, Artificial intelligence, Luxembourg, Company, Silicon, SOC, Ecosystem, GDDR6, TWSE, ASIC, Taiwan Stock Exchange, Socs, Cloud computing, IP, HBM3, DDR5, TSMC, GLOBE, Machine learning, UCL Business, Mobile phone, Semiconductor, Alchip

Taipei, Taiwan, June 15, 2022 (GLOBE NEWSWIRE) -- Alchip Technologies today announced that its high-performance computing ASIC services are now taking 3nm designs and targeting its first test chip for Q1 2023.

Key Points: 
  • Taipei, Taiwan, June 15, 2022 (GLOBE NEWSWIRE) -- Alchip Technologies today announced that its high-performance computing ASIC services are now taking 3nm designs and targeting its first test chip for Q1 2023.
  • Alchip becomes the first dedicated high-performance ASIC company to announce total design readiness of their design and production ecosystem.
  • Design methodology, design technology and infrastructure and test chips specification had all been finalized at the end of last year.
  • For a more information on Alchip, go to www.alchip.com
    Alchip Technologies Ltd., headquartered in Taipei, Taiwan, is a leading global provider of silicon design and production services for system companies developing complex and high-volume ASICs and SoCs.

Qualigen Therapeutics Secures Option to Negotiate License for G-Quadruplex Anti-Cancer Technology from UCL

Retrieved on: 
понедельник, марта 1, 2021
University College London, Technology transfer, UCL Business

Research at UCL, supported by the UCL Technology Fund, has shown encouraging results using GQBs and targeted cancer therapeutics, particularly for the treatment of pancreatic cancer.

Key Points: 
  • Research at UCL, supported by the UCL Technology Fund, has shown encouraging results using GQBs and targeted cancer therapeutics, particularly for the treatment of pancreatic cancer.
  • Qualigen has secured an option to pursue a worldwide commercial license for this promising technology from UCL Business Ltd, the commercialization company of UCL.
  • This agreement with UCL will allow Qualigen to study a significant potential indication for ALAN with improved selectivity for pancreatic cancer cells.
  • UCL Business Ltd (UCLB), part of UCL Innovation & Enterprise, is the commercialisation company for UCL.

DiNAQOR AG Announces Research Collaboration and License Agreement with UCL to Investigate Gene Therapies for Heart Failure

Retrieved on: 
понедельник, января 13, 2020
Articles, Branches of biology, Life sciences, Technology transfer, UCL Business, Gene therapy, Therapy, Great Ormond Street Hospital, University College London

Under the terms of the agreement, DiNAQOR and UCL will collaborate to advance DiNAQOR's two discovery cardiac gene therapy programs into clinical development.

Key Points: 
  • Under the terms of the agreement, DiNAQOR and UCL will collaborate to advance DiNAQOR's two discovery cardiac gene therapy programs into clinical development.
  • The license agreement was carried out by UCL's technology commercialisation company, UCL Business Ltd (UCLB), part of UCL Innovation & Enterprise.
  • Based on the research of Professor Thomas Voit at the UCL GOSH Institute of Child Health,the agreement aims to utilise UCL's leading expertise in gene therapy.
  • "This partnership represents an exceptional opportunity to accelerate development of potentially life-saving gene therapies for patients suffering from heart failure.